Letter by Reddy et al Regarding Article, “Cannabis Use and Outcomes in Patients With Aneurysmal Subarachnoid Hemorrhage” To the Editor: We read with great interest the article by Behrouz et al. In light of recent movements for widespread legalization of recreational marijuana, the adverse effects of cannabis remain a pressing area of research. Behrouz et al present a retrospective cohort analys...

BACKGROUND Myocardial injury after aneurysmal subarachnoid hemorrhage (aSAH) is associated with poor outcomes. Delayed cerebral ischemia (DCI) is also a complication of aSAH. We sought to determine whether (1) DCI could be predicted by demographics, aSAH severity/aneurysm location, or aSAH-associated myocardial injury (SAHMI), and (2) DCI is associated with increased mortality after aSAH. MET...

Objective Patients with aneurysmal subarachnoid hemorrhage (aSAH) experience high mortality and morbidity. Neuroinflammation causes brain damage expansion after aSAH. Due to the complexity of the inflammatory response multiple biomarkers are needed to evaluate its' progression. We studied inflammatory process after aSAH by measuring two inflammatory biomarkers, interleukin-6 (IL-6) and high-mob...

Cerebral vasospasm (CVS) is a common and severe complication of aneurysmal subarachnoid hemorrhage (aSAH). Despite the improvement in treatment of aSAH, CVS complicating aSAH has remained the main cause of death. CVS begins most often on the third day after the ictal event and reaches the maximum on the 5th–7th postictal days. Several therapeutic modalities have been employed to prevent or reve...

Background: Aneurysmal subarachnoid hemorrhage (aSAH) is still a fatal and morbid disease, although bleeding aneurysms can be secured in almost all cases. Occurrence of post-SAH complications including cerebral vasospasm, delayed cerebral ischemia, hydrocephalus, epilepsy, and infections are the main determinants of clinical outcome. Hence, it is important to search for early predictors for spe...

AIM Shunt-dependent hydrocephalus (SDH) is a relatively common complication following aneurysmal subarachnoid hemorrhage (aSAH). Delay in diagnosis and treatment may worsen neurological outcome. This study was conducted to identify early clinical factors associated with SDH following aSAH. MATERIAL AND METHODS Patients diagnosed with aSAH at our hospital from January 2010 through July 2014 we...

OBJECTIVE To investigate the difference between myocardial injuries caused by nonaneurysmal subarachnoid hemorrhage (SAH) or aneurysmal SAH. PATIENTS AND METHODS A total of 92 inpatients with SAH at early stage (within 48h), who were treated in our hospital from 2008 to 2014 were enrolled in this study. Differences in cerebral-cardiac syndrome seen in perimesencephalic subarachnoid hemorrhage...

Aneurysmal subarachnoid hemorrhage (aSAH) is associated with significant mortality rates, and most survivors experience significant cognitive deficits across multiple domains, including executive function. It is critical to determine the neural basis for executive deficits in aSAH, in order to better understand and improve patient outcomes. This study is the first examination of resting-state f...

BACKGROUND AND PURPOSE The joint effect of risk factors on the risk of aneurysmal SAH (aSAH) has been studied sparsely. METHODS We examined the potential synergism between cigarette smoking, hypertension, and regular alcohol consumption and the risk of aSAH in a prospective, population-based cohort of participants from the Nord-Trøndelag Health Study and the Tromsø Study in Norway. Interactio...

The prognosis of aneurysmal subarachnoid hemorrhage (aSAH) has improved during the past decades. However, a recent hospital-based study showed that 90-day case fatality is still 30%. Determinants of functional outcome after aSAH may include the severity of the initial hemorrhage, rebleeding of the aneurysm, and cerebral ischemia that can be distinguished into (1) acute ischemia at the time of b...